Healthcare provider profile · identity verified

James Morley Doe, MD

Internal Medicine · TUCSON, AZ · NPI 1558523191

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	394	131
Lisinopril	Lisinopril	256	82
Amlodipine Besylate	Amlodipine Besylate	217	84
Gabapentin	Gabapentin	165	49
Levothyroxine Sodium	Levothyroxine Sodium	163	56
Losartan Potassium	Losartan Potassium	162	55
Metformin Hcl	Metformin Hcl	119	39
Albuterol Sulfate Hfa	Albuterol Sulfate	102	37
Rosuvastatin Calcium	Rosuvastatin Calcium	101	33
Omeprazole	Omeprazole	99	32
Trazodone Hcl	Trazodone Hcl	99	38
Pantoprazole Sodium	Pantoprazole Sodium	87	39
Hydrochlorothiazide	Hydrochlorothiazide	79	33
Tamsulosin Hcl	Tamsulosin Hcl	77	25
Simvastatin	Simvastatin	72	20
Metformin Hcl Er	Metformin Hcl	67	25
Ozempic	Semaglutide	67	17
Allopurinol	Allopurinol	62	22
Escitalopram Oxalate	Escitalopram Oxalate	58	23
Metoprolol Succinate	Metoprolol Succinate	57	22
Potassium Chloride	Potassium Chloride	57	23
Sertraline Hcl	Sertraline Hcl	46	15
Carvedilol	Carvedilol	44	12
Duloxetine Hcl	Duloxetine Hcl	44	17
Alendronate Sodium	Alendronate Sodium	43	15
Eliquis	Apixaban	42	14
Montelukast Sodium	Montelukast Sodium	40	16
Fluticasone Propionate	Fluticasone Propionate	39	16
Furosemide	Furosemide	38	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	37	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	15
Pravastatin Sodium	Pravastatin Sodium	37	11
Clopidogrel	Clopidogrel Bisulfate	35	15
Jardiance	Empagliflozin	32	12
Prednisone	Prednisone	32	14
Xarelto	Rivaroxaban	31	suppressed
Famotidine	Famotidine	30	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	suppressed
Acyclovir	Acyclovir	29	suppressed
Chlorthalidone	Chlorthalidone	29	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	27	13
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Glipizide	Glipizide	26	suppressed
Tizanidine Hcl	Tizanidine Hcl	26	11
Ezetimibe	Ezetimibe	25	suppressed
Celecoxib	Celecoxib	24	suppressed
Mounjaro	Tirzepatide	24	suppressed
Estradiol	Estradiol	21	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Cephalexin	Cephalexin	20	17
Diclofenac Sodium	Diclofenac Sodium	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Atenolol	Atenolol	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	14
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Temazepam	Temazepam	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	11
Azithromycin	Azithromycin	13	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Finasteride	Finasteride	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Naproxen	Naproxen	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error